Effect of Repetitive Transcranial Magnetic Stimulation approved by FDA (rTMS-FDA) versus Repetitive Transcranial Magnetic Stimulation with concentration on Mirror Neuron System (rTMS-MNS) on emotion and mood regulation in patients with major depressive disorder
Phase 2
- Conditions
- Major depression.Severe depressive episode with psychotic symptoms
- Registration Number
- IRCT201610209014N123
- Lead Sponsor
- Vice-chancellor for Research the Technology, Hamadan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
major depressive disorder; age of 18 to 65 years; receiving standard anti-depression drugs.
Exclusion criteria: pregnancy; drug abuse during the last month; drug addiction during the last six months; neurologic disease or convulsion; having metal implant; using lorazepam, benzodiazepines, monoamine oxidase enzyme inhibitors or bupropion in the last month.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assessing excitement regulation. Timepoint: before and 2 and 4 weeks after intervention. Method of measurement: using excitement adequacy ranking scale.;Assessing mood regulation. Timepoint: before and 2 and 4 weeks after intervention. Method of measurement: using POMS criteria.;Assessing social perception. Timepoint: before and 2 and 4 weeks after intervention. Method of measurement: by reading mind in the eyes.
- Secondary Outcome Measures
Name Time Method